silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com
Company profile
Ticker
SLN, SLNCF
Exchange
Website
CEO
Craig A. Tooman
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
SLN stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
13 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
23 Feb 24
6-K
Securities Purchase Agreement
6 Feb 24
6-K
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
1 Dec 23
6-K
Current report (foreign)
14 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K/A
Current report (foreign) (amended)
29 Aug 23
6-K
Current report (foreign)
16 Aug 23
S-8
Registration of securities for employees
1 Aug 23
Latest ownership filings
SC 13D/A
Griffiths Richard Ian
27 Mar 24
SC 13G/A
Lombard Odier Asset Management (USA) Corp
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
12 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G
Artal International S.C.A.
1 Sep 23
SC 13D/A
Griffiths Richard Ian
14 Aug 23
SC 13G/A
TCG Crossover GP I, LLC
14 Feb 23
SC 13G/A
Lombard Odier Asset Management (USA) Corp
14 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
64.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 21 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 92.44 bn |
Total shares | 19.23 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lombard Odier Asset Management | 4.12 mm | $18.67 bn |
Lombard Odier Asset Management | 3.42 mm | $18.78 bn |
TCG Crossover Management | 2.10 mm | $11.58 bn |
Deep Track Capital | 1.95 mm | $10.73 bn |
Artal | 1.70 mm | $9.35 mm |
BVF | 1.51 mm | $8.30 bn |
Aquilo Capital Management | 1.31 mm | $7.22 bn |
Frazier Life Sciences Management | 881.17 k | $4.85 bn |
GS Goldman Sachs | 410.00 k | $2.26 bn |
M28 Capital Management | 363.80 k | $2.00 bn |
News
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
15 Mar 24
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
14 Mar 24
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $45
14 Mar 24
Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $42
14 Mar 24
What 4 Analyst Ratings Have To Say About Silence Therapeutics
13 Mar 24
Press releases
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
13 Mar 24
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
13 Mar 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
23 Feb 24
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
5 Feb 24
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31 Jan 24